Head-to-head evidence
Anagliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Anagliptin · Suiny
Marketed by JW Pharmaceutical
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
Trelagliptin · Zafatek
Developed by Takeda Pharmaceutical Company
NCT03940183 · Phase 3 · completed
The trial randomized 254 participants to trelagliptin or placebo and used quadruple blinding. Its primary endpoint was the surrogate measure of change in HbA1c at week 24, but results were not posted, so whether the comparison favored trelagliptin is unknown.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Trelagliptin's landscape